A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

Prostate Cancer Clinical Trial

Official title:

A Randomized Phase II Clinical Trial of Two Dose-levels of Itraconazole in Patients With Metastatic Castration-resistant Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00887458
• Other study ID #: J0932
• Secondary ID: JHMI-IRB number:
• Status: Completed
• Phase: Phase 2
• First received: April 23, 2009
• Last updated: September 13, 2017
• Start date: July 2009
• Est. completion date: December 2013

Study information

• Verified date: September 2017
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research is being done to test an investigational drug, called itraconazole, in the treatment of prostate cancer. Itraconazole is approved by the Food and Drug Administration (FDA) for the treatment of various fungal infections such as fingernail/toenail infections and other more serious fungal infections. The word "investigational" means that itraconazole is not approved for use in people with cancer. However, the FDA is allowing the use of itraconazole in this research study. Itraconazole has been shown to have activity against cancer (including prostate cancer) in the laboratory, but has not been tested against cancer in humans.

The purpose of this study is to find out:

• If itraconazole is safe when given at two different doses

• How itraconazole affects prostate specific antigen (PSA): a blood test that measures substances released by prostate cancer

• Whether itraconazole can delay further prostate cancer growth and spread

• How itraconazole affects other markers of prostate cancer

Description:

Itraconazole is an oral, generic, and commercially available antifungal drug with a long safety record when used at doses ranging from 200 to 600 mg daily.

Itraconazole has been shown in cellular and animal models to be a potent angiogenesis inhibitor as well as a Hedgehog pathway antagonist; both pathways are considered important in prostate cancer. Itraconazole has not previously been tested as an antineoplastic agent, but given its well-established safety profile, the gap between further preclinical studies and human clinical trials can be narrowed to accelerate development of this agent as a putative anticancer drug. The investigators hypothesize that itraconazole will prevent PSA progression in a significant proportion of men with metastatic CRPC and that it will have an acceptable safety profile at both doses. Itraconazole may ultimately delay the need for chemotherapy in these men.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 46
• Est. completion date: December 2013
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed prostate adenocarcinoma.

• Presence of distant metastases on bone scan, CT scan, or MRI scan.

• Progression after androgen deprivation (and anti-androgen withdrawal).

• Rising serum PSA (Prostate Cancer Working Group (PCWG2) definition).

• Castrate levels of serum testosterone (i.e., = 50 ng/dL).

• Age > 18 years.

• ECOG performance status score = 2, and/or Karnofsky score = 50%.

• Life expectancy > 6 months.

• Adequate kidney, liver, and bone marrow function.

• Willingness to sign informed consent and adhere to study requirements.

Exclusion Criteria:

• Recent surgery, radiation therapy, combined androgen blockade, or investigational therapies in the last 8 weeks.

• Previous chemotherapy for metastatic prostate cancer.

• Concomitant use of second-line hormonal agents (e.g., ketoconazole, DES)

• Current use of corticosteroids, except if on a stable dose for = 3 months.

• History of malabsorption syndrome (may affect itraconazole absorption).

• Allergic reactions to itraconazole or similar compounds.

• Concurrent use of drugs that interact with the CYP3A4 system (caution only).

• Presence of known brain metastases.

• Prior malignancy in the last 3 years, with some exceptions.

• Uncontrolled major infectious, cardiac, or pulmonary illnesses.

• Prolonged corrected QT interval (> 450 msec) on electrocardiography.

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Itraconazole 200 mg
Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
• Itraconazole 300mg
Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)

Locations

Country	Name	City	State
United States	University of Michigan Comprehensive Cancer Center	Ann Arbor	Michigan
United States	Johns Hopkins Hospital	Baltimore	Maryland
United States	Karmanos Cancer Center	Detroit	Michigan
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy With One of Two Dose-levels of Itraconazole: 200 mg or 600 mg Daily.	To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy. "PSA progression" is defined as a 25% increase in PSA over baseline [or nadir (lowest)] and an increase in absolute PSA level by at least 2 ng/mL, both confirmed by a second value at least 4 weeks later.	Up to 24 weeks
Secondary	To Determine the Proportion of Men With = 50% PSA Reduction From Baseline.	Will be reported as the percentage of men with = 50% PSA reduction from baseline.	Baseline and approximately 2 years from open enrollment